Publication: Glycans flanking the hypervariable connecting peptide between the a and B strands of the V1/V2 domain of HIV-1 gp120 confer resistance to antibodies that neutralize CRF01-AE viruses
Issued Date
2015-03-20
Resource Type
ISSN
19326203
Other identifier(s)
2-s2.0-84925967803
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
PLoS ONE. Vol.10, No.3 (2015)
Suggested Citation
Sara M. O'Rourke, Ruengpung Sutthent, Pham Phung, Kathryn A. Mesa, Normand L. Frigon, Briana To, Navin Horthongkham, Kay Limoli, Terri Wrin, Phillip W. Berman Glycans flanking the hypervariable connecting peptide between the a and B strands of the V1/V2 domain of HIV-1 gp120 confer resistance to antibodies that neutralize CRF01-AE viruses. PLoS ONE. Vol.10, No.3 (2015). doi:10.1371/journal.pone.0119608 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/35192
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Glycans flanking the hypervariable connecting peptide between the a and B strands of the V1/V2 domain of HIV-1 gp120 confer resistance to antibodies that neutralize CRF01-AE viruses
Abstract
© 2015 O'Rourke et al. Understanding the molecular determinants of sensitivity and resistance to neutralizing antibodies is critical for the development of vaccines designed to prevent HIV infection. In this study, we used a genetic approach to characterize naturally occurring polymorphisms in the HIV envelope protein that conferred neutralization sensitivity or resistance. Libraries of closely related envelope genes, derived from virus quasi-species, were constructed from individuals infected with CRF01-AE viruses. The libraries were screened with plasma containing broadly neutralizing antibodies, and neutralization sensitive and resistant variants were selected for sequence analysis. In vitro mutagenesis allowed us to identify single amino acid changes in three individuals that conferred resistance to neutralization by these antibodies. All three mutations created N-linked glycosylation sites (two at N136 and one at N149) proximal to the hypervariable connecting peptide between the C-terminus of the A strand and the N-terminus of the B strand in the four-stranded V1/V2 domain β-sheet structure. Although N136 has previously been implicated in the binding of broadly neutralizing monoclonal antibodies, this glycosylation site appears to inhibit the binding of neutralizing antibodies in plasma from HIV-1 infected subjects. Previous studies have reported that the length of the V1/V2 domain in transmitted founder viruses is shorter and possesses fewer glycosylation sites compared to viruses isolated from chronic infections. Our results suggest that vaccine immunogens based on recombinant envelope proteins from clade CRF01-AE viruses might be improved by inclusion of envelope proteins that lack these glycosylation sites. This strategy might improve the efficacy of the vaccines used in the partially